Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: Case report series

Arquivos Brasileiros de Oftalmologia

Volumn 76, Issue 3, 2013, Pages 180-184

  De Freitas, Luiz Guilherme Azevedo ^a,b   Isaac, David Leonardo Cruvinel ^b   Tannure, William Thomas ^b   Gabriel, Luís Alexandre Rassi ^b   Dos Reis, Ricardo Gomes ^b   Rassi, Alan Ricardo ^b   De Freitas, Clovis Arcoverde ^c   De Ávila, Marcos Pereira ^b,c  

^a Hospital de Olhos Santa Luzia   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c Centro Brasileiro DaVisao CBV   (Brazil)

Author keywords

Angiogenesis inhibitors therapeutic use; Choroidal neovascularization etiology; Intravitreal injections; Macular degeneration complications; Optical coherence tomography; Retina

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; AGED; ARTICLE; DRUG COMBINATION; EVALUATION STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84883715348     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492013000300010     Document Type: Article

References (25)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122(4):477-85.
2. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127(4):533-40. Comment in: JAMA. 2009;301(20):2152-3.
3. Chandra SR, Gragoudas ES, Friedman E, Van Buskirk EM, Klein ML. Natural history of disciform degeneration of the macula. Am J Ophthalmol. 1974;78(4):579-82.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. Comment in: N Engl J Med. 2006; 355(14):1493-5. N Engl J Med. 2006;355(14):1409-12. N Eng J Med. 2007;356(7):748-9; author reply 749-50. N Engl J Med. 2007;356(7):747-8; author reply 749-50.
5. Brown G. Comparative effectiveness. Curr Opin Ophthalmol. 2008;19(3):175-6.
6. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-24.e1.
7. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variabledosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.e1. Comment in: Am J Ophthalmol. 2009; 148(1):1-3.
8. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908. Comment in: Clin Experiment Ophthalmol. 2011;39(7):718-20. N Engl J Med. 2011;365(23):2238; N Engl J Med. 2011;365(23):2237; author reply 2237. N Engl J Med. 2011;364(20):1966-7.
9. Lima Filho AA, Dantas AM, Sallum JM, Ferreira Filho N, Marback RL, Org. Bases da Oftalmologia. Rio de Janeiro: Cultura Médica; 2008. v. 1. p.429-38.
10. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular agerelated macular degeneration following infliximab therapy. Am J Ophthalmol. 2005; 139(3):537-40.
11. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30(1):71-80.
12. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol, 2009; 247(2):273-81.
13. Rassi AR, Rigueiro MP, Isaac DL, Dourado L, Abud MB, Freitas EC, et al. [A safety study of retinal toxicity after serial intravitreal injections of infliximab in rabbits eyes]. Arq Bras Oftalmol. 2011t;74(5):352-6. Portuguese.
14. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009;147(5):825-30, 830.e1.
15. Magalhães FP, Costa EF, Cariello AJ, Rodrigues EB, Hofling-Lima AL. Comparative analysis of the nuclear lens opalescence by the Lens Opacities Classification System III with nuclear density values provided by Oculus Pentacam: a cross-section study using Pentacam Nucleus Staging software. Arq Bras Oftalmol. 2011;74(2):110-3.
16. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28(2):117-44.
17. Marcelo LG, Thelma LS. Principais imunomoduladores. In: Marcelo LG, Thelma LS. Reumato-oftalmologia. São Paulo: Tecmedd; 2007. Cap. 6. p.94-102.
18. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci [Internet]. 1999[cited 2011 Dec 21];40(9):1891-8. Available from: http://www.iovs.org/content/40/9/1891.long
19. De Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci[Internet]. 1994[cited 2011 Nov 24];35(11):3873-83. Available from: http://www. iovs.org/content/35/11/3873.long
20. Derevjanik NL, Vinores SA, Xiao WH, Mori K, Turon T, Hudish, T, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci [Internet]. 2002[cited 2012 Sep 15]43(7):2462-7. Available from: http://www. iovs.org/content/43/7/2462.long
21. Limb GA, Hollifield RD, Webste, L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci [Internet]. 2001[cited 2011 Jun 21];42(7):1586-91. Available from: http://www.iovs.org/content/42/7/1586.long
22. Theodossiadis PG, Markomichelaki, NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27(4):399-413.
23. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina. 2010;30(10):1601-8.
24. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011; 31(2):298-303.Comment in: Retina. 2012;32(10):2179; author reply 2179-80.
25. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30(1):71-80.